OR WAIT null SECS
Today, Bristol-Myers Squibb Co. announced labeling changes for Tequin (gatifloxacin), an antibiotic indicated for the treatment of patients with pneumonia, bronchitis, uncomplicated gonorrhea, and various infections including infections of urinary tract, kidneys, and skin.
The labeling changes, announced by the Tequin manufacturer in a letter to healthcare professionals, update the prescription information as a result of continued reports of serious cases of hypoglycemia and hyperglycemia in patients receiving Tequin. Since the approval of Tequin in 1999, there have been rare cases of life-threatening events reported globally in patients treated with the drug. Most of these events were reversible when properly managed, but a few had fatal outcomes.
Information about the risks of low blood sugar and high blood sugar was added to the Warnings section of the U.S. labeling in 2002. Today's changes strengthen the existing Warning on hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar), add a contraindication for use in diabetic patients, and include information identifying other risk factors for developing low blood sugar and high blood sugar, including advanced age, renal insufficiency, and concomitant glucose altering medications while taking Tequin.
The FDA says it will continue monitoring Tequin's safety to ensure that its benefits outweigh the risks to patients.